Market price and medical insurance reimbursement of Opicapone in 2025

Opicapone is a third-generation oral COMT inhibitor. It is mainly used for dopamine replacement therapy in patients with Parkinson's disease. It assists in prolonging the efficacy of levodopa and improves the "on-off" phenomenon. As a new targeted drug, Opicapone can significantly reduce motion fluctuations and improve patients' quality of life clinically. Since it is not yet available in China, patients have certain limitations in access and payment.

As of2025, Opicapone has not yet been launched in China’s domestic pharmaceutical market, so domestic patients cannot purchase it directly through hospitals or pharmacies. If patients need to use the drug, they must rely on formal overseas channels to import it, usually through overseas pharmacies or international medical transport services. This method of purchasing is not only more costly, but also requires compliance with import and customs declaration regulations.

In overseas markets, only the original version of Opicapone is currently sold, and no generic version has yet appeared. Taking the European version as an example, the price of each box is about more than 2,000 yuan. The specific price fluctuates due to differences in region, exchange rate and channel. Compared with other Parkinson's disease auxiliary drugs that have been marketed in China, the price of Opicapone is at the mid-to-high end, which also makes patients need to consider the financial burden in long-term medication.

Since Opicapone has not yet been marketed in China and has not been included in the medical insurance system, domestic patients cannot reimburse the cost of the drug through medical insurance. It is recommended that patients first communicate with professional doctors when considering use, evaluate the necessity and feasibility of use, and plan funds reasonably. In addition, paying attention to the status of drug launches in China and policy updates that may be included in medical insurance will also help reduce the financial burden on patients and achieve safe and standardized treatment in the future.

Reference link:https://www.drugs.com